Literature DB >> 35794185

Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern.

Greet Vanderlinden1, Jenny Ceccarini2, Thomas Vande Casteele3, Laura Michiels4,5,6, Robin Lemmens4,5,6, Eric Triau7, Kim Serdons8, Jos Tournoy9,10, Michel Koole2, Mathieu Vandenbulcke3,11, Koen Van Laere2,8.   

Abstract

Next to amyloid and tau, synaptic loss is a key pathological hallmark in Alzheimer's disease, closely related to cognitive dysfunction and neurodegeneration. Tau is thought to cause synaptic loss, but this has not been experimentally verified in vivo. In a 2-year follow-up study, dual tracer PET-MR was performed in 12 amnestic MCI patients using 18F-MK-6240 for tau and 11C-UCB-J for SV2A as a proxy for synaptic density. Tau already accumulated in the neocortex at baseline with progression in Braak V/VI at follow-up. While synaptic loss was limited to limbic regions at baseline, it followed the specific tau pattern to stage IV/V regions two years later, indicating that tau spread might drive synaptic vulnerability. Moreover, synaptic density changes correlated to changes in cognitive function. This study shows for the first time in vivo that synaptic loss regionally follows tau accumulation after two years, providing a disease-modifying window of opportunity for (combined) tau-targeting therapies.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35794185     DOI: 10.1038/s41380-022-01672-x

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  49 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

2.  What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies.

Authors:  Victor L Villemagne; Brian J Lopresti; Vincent Doré; Dana Tudorascu; Milos D Ikonomovic; Samantha Burnham; Davneet Minhas; Tharick A Pascoal; N Scott Mason; Beth Snitz; Howard Aizenstein; Chester A Mathis; Oscar Lopez; Christopher C Rowe; William E Klunk; Ann D Cohen
Journal:  J Nucl Med       Date:  2020-12-31       Impact factor: 10.057

Review 3.  The complexity of tau in Alzheimer's disease.

Authors:  Nima N Naseri; Hong Wang; Jennifer Guo; Manu Sharma; Wenjie Luo
Journal:  Neurosci Lett       Date:  2019-04-25       Impact factor: 3.046

4.  Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau.

Authors:  Joseph McInnes; Keimpe Wierda; An Snellinx; Laura Bounti; Yu-Chun Wang; Ilie-Cosmin Stancu; Nuno Apóstolo; Kris Gevaert; Ilse Dewachter; Tara L Spires-Jones; Bart De Strooper; Joris De Wit; Lujia Zhou; Patrik Verstreken
Journal:  Neuron       Date:  2018-02-01       Impact factor: 17.173

5.  Test-retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer's disease.

Authors:  Cristian Salinas; Talakad G Lohith; Ajay Purohit; Arie Struyk; Cyrille Sur; Idriss Bennacef; John Beaver; Laurent Martarello
Journal:  J Cereb Blood Flow Metab       Date:  2019-11-11       Impact factor: 6.200

6.  Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects.

Authors:  Alexandra Gogola; Davneet S Minhas; Victor L Villemagne; Ann D Cohen; James M Mountz; Tharick A Pascoal; Charles M Laymon; N Scott Mason; Milos D Ikonomovic; Chester A Mathis; Beth E Snitz; Oscar L Lopez; William E Klunk; Brian J Lopresti
Journal:  J Nucl Med       Date:  2021-04-16       Impact factor: 11.082

7.  Tau association with synaptic vesicles causes presynaptic dysfunction.

Authors:  Lujia Zhou; Joseph McInnes; Keimpe Wierda; Matthew Holt; Abigail G Herrmann; Rosemary J Jackson; Yu-Chun Wang; Jef Swerts; Jelle Beyens; Katarzyna Miskiewicz; Sven Vilain; Ilse Dewachter; Diederik Moechars; Bart De Strooper; Tara L Spires-Jones; Joris De Wit; Patrik Verstreken
Journal:  Nat Commun       Date:  2017-05-11       Impact factor: 14.919

8.  Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue.

Authors:  Cinthya Aguero; Maeva Dhaynaut; Marc D Normandin; Ana C Amaral; Nicolas J Guehl; Ramesh Neelamegam; Marta Marquie; Keith A Johnson; Georges El Fakhri; Matthew P Frosch; Teresa Gomez-Isla
Journal:  Acta Neuropathol Commun       Date:  2019-03-11       Impact factor: 7.801

Review 9.  Tau PET imaging in neurodegenerative tauopathies-still a challenge.

Authors:  Antoine Leuzy; Konstantinos Chiotis; Laetitia Lemoine; Per-Göran Gillberg; Ove Almkvist; Elena Rodriguez-Vieitez; Agneta Nordberg
Journal:  Mol Psychiatry       Date:  2019-01-11       Impact factor: 15.992

10.  P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice.

Authors:  Zhi Ruan; Jean-Christophe Delpech; Srinidhi Venkatesan Kalavai; Alicia A Van Enoo; Jianqiao Hu; Seiko Ikezu; Tsuneya Ikezu
Journal:  Mol Neurodegener       Date:  2020-08-18       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.